RATIONALE AND OBJECTIVES: Evaluate qualitative dynamic contrast-enhanced magnetic resonance imaging (MRI) characteristics of normal central zone based on recently described central zone MRI features.
MATERIALS AND METHODS: Institutional review board-approved, Health Insurance Portability and Accountability Act compliant study, 59 patients with prostate cancer, histopathology proven to not involve central zone or prostate base, underwent endorectal MRI before prostatectomy. Two readers independently reviewed T2-weighted images and apparent diffusion coefficient (ADC) maps identifying normal central zone based on low signal intensity and location. Next, two readers drew bilateral central zone regions of interest on dynamic contrast-enhanced magnetic resonance images in consensus and independently recorded enhancement curve types as type 1 (progressive), type 2 (plateau), and type 3 (wash-out). Identification rates of normal central zone and enhancement curve type were recorded and compared for each reviewer. The institutional review board waiver was approved and granted 05/2010.
RESULTS: Central zone identified in 92%-93% of patients on T2-weighted images and 78%-88% on ADC maps without significant difference between identification rates (P = .63 and P = .15 and inter-reader agreement (κ) is 0.64 and 0.29, for T2-weighted images and ADC maps, respectively). All central zones were rated either curve type 1 or curve type 2 by both radiologists. No statistically significant difference between the two radiologists (P = .19) and inter-reader agreement was κ = 0.37.
CONCLUSIONS: Normal central zone demonstrates either type 1 (progressive) or type 2 (plateau) enhancement curves on dynamic contrast-enhanced MRI that can be potentially useful to differentiate central zone from prostate cancer that classically demonstrates a type 3 (wash-out) enhancement curve.
Written by:
Hansford BG, Karademir I, Peng Y, Jiang Y, Karczmar G, Thomas S, Yousuf A, Antic T, Eggener S, Oto A. Are you the author?
Department of Radiology, University of Chicago Medicine, 5841 South Maryland Ave, MC2026, Chicago, IL 60637; Department of Pathology, University of Chicago Medicine, Chicago, IL.
Reference: Acad Radiol. 2014 May;21(5):569-77.
doi: 10.1016/j.acra.2014.01.013
PubMed Abstract
PMID: 24703469
UroToday.com Prostate Cancer Section
